2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Thyroid Nodule
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Solitary Fibrous Tumors
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pruritus
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Parathyroid Neoplasms
1
Parathyroid Diseases
1
Ovarian Neoplasms
1
Opioid-Related Disorders
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Lung Neoplasms
1
Lower Urinary Tract Symptoms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Interventions
Dexamethasone
809
Bortezomib
449
Lenalidomide
430
Cyclophosphamide
336
Melphalan
251
Calcium Dobesilate
237
daratumumab
218
pomalidomide
202
carfilzomib
181
fludarabine phosphate
131
Thalidomide
121
fludarabine
118
Peripheral Blood Stem Cell Transplantation
117
Filgrastim
111
ixazomib
85
Mycophenolic Acid
85
Granulocyte Colony-Stimulating Factor
84
Busulfan
83
Whole-Body Irradiation
80
Tacrolimus
75
dexamethasone acetate
74
Cyclosporine
67
isatuximab
64
Prednisone
64
dexamethasone 21-phosphate
63
elotuzumab
60
auricularum
57
belantamab mafodotin
55
Antilymphocyte Serum
55
Etoposide
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Capsules
×
Clear all
NCT02756663
2016-11-08
PANORAMA-5
Novartis
Phase 2
Withdrawn